Hormonal
Testosterone treatment in older men with low testosterone increases coronary artery noncalcified plaque volume, but was not associated with more cardiovascular or prostate adverse events over 12 months.
If you are an older man with confirmed low testosterone, testosterone therapy may increase your coronary artery noncalcified plaque volume, but this was not associated with more cardiovascular or prostate adverse events over 12 months. The treatment involves daily application of a gel, with dose adjustments to keep levels in the normal range for young men. Long-term safety requires more data.
In the Cardiovascular Trial, testosterone increased the coronary artery noncalcified plaque volume as assessed using computed tomographic angiography. Although testosterone was not associated with more cardiovascular or prostate adverse events than placebo, a trial of a much larger number of men for a much longer period would be necessary to determine whether testosterone increases cardiovascular or prostate risk.
Why this rating
Based on a large, placebo-controlled, double-blind randomized trial, but the effect on plaque volume is a surrogate marker, and the clinical significance is uncertain.
Source
Lessons From the Testosterone Trials
Peter J. Snyder et al. · Endocrine Reviews · 2018
DOI 10.1210/er.2017-00234
More from this paper
- Testosterone treatment in older men with unequivocally low testosterone levels significantly improves sexual activity, libido, and erectile function.Strong
- Testosterone treatment in older men with low testosterone improves hemoglobin levels and corrects anemia, regardless of the cause of anemia.Strong
- Testosterone treatment in older men with low testosterone increases volumetric bone mineral density and estimated bone strength, but does not significantly improve areal bone mineral density.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →